Tech Company Financing Transactions
ProFound Therapeutics Funding Round
ProFound Therapeutics secured a $75 million Seed venture capital round on 5/26/2022. Investors included Flagship Pioneering.
Transaction Overview
Company Name
Announced On
5/26/2022
Transaction Type
Venture Equity
Amount
$75,000,000
Round
Seed
Investors
Flagship Pioneering (Lead Investor) (Avak Kahvejian)
Proceeds Purpose
we will focusing on proteins in the process of translation, together with the innovative application of technology and new biological insights, we have found tens of thousands of undiscovered human proteins that could provide countless new intervention points across diseases.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Undisclosed
Undisclosed, Undisclosed
USA
Undisclosed, Undisclosed
USA
Phone
Undisclosed
Website
Email Address
Overview
In 2019, ProFound's founding team of Noubar Afeyan, Avak Kahvejian, Yann Echelard, Vini Mani, and Erica Weinstein were inspired by a belief that there existed "proteomic dark matter" -- peptides and proteins -- that could potentially be detected but had thus far gone unannotated and ignored, along with aberrations in the human genome that play unexplained roles in disease. Hypothesizing that there must be a link, we began to explore the white space of proteomics.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Noubar Afeyan
Chief Executive Officer
Avak Kahvejian
President
Kala Subramanian
Browse more venture capital transactions:
Prev: 5/26/2022: Bibit venture capital transaction
Next: 5/26/2022: Enhanced Digital Group venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on funding rounds that are announced publicly. VC investment data records reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs